Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1668-1674

  Mocikova, Heidi ^a   Pytlik, Robert ^b   Markova, Jana ^a   Steinerova, Katerina ^c   Kral, Zdenek ^d   Belada, David ^e   Trnkova, Marie ^f   Trneny, Marek ^b   Koza, Vladimir ^c   Mayer, Jiri ^d,g   Zak, Pavel ^e   Kozak, Tomas ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f Czech Stem Cells Registry (CSCR)   (Czech Republic)

^g CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

Author keywords

autologous stem cell transplant; Hodgkin lymphoma; PET

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; VINBLASTINE; VINDESINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052064622     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.573889     Document Type: Article

References (27)

1. Moskowitz CH, Nimer SD, Zelentz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623. (Pubitemid 32113392)
2. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002;20: 221-230. (Pubitemid 34032615)
3. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-123. (Pubitemid 40124488)
4. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
5. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006;38:211-216. (Pubitemid 44102948)
6. Spaepen K, Stroobants S, Dupot P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lympho-ma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53-59. (Pubitemid 36759635)
7. Schot BW, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 2003;123:282-287. (Pubitemid 37305063)
8. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260-267. (Pubitemid 34145144)
9. Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:2496-2503.
10. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890-897.
11. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486-491. (Pubitemid 46105942)
12. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre-and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007;110:1361-1369. (Pubitemid 47435610)
13. Cremerius U, Fabry U, Wildberger J, et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FGD) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;30:103-111.
14. Filmont JE, Czernin J, Yap C, et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem cell transplantation. Chest 2003;124:608-613. (Pubitemid 37000141)
15. Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by auto-logous stem cell transplantation. Leuk Lymphoma 2008;49: 727-733. (Pubitemid 351517218)
16. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeox-yglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010;15:750-759.
17. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102: 1989-1996. (Pubitemid 37122371)
18. Palmer J, Goggins T, Broadwater G, et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2010 Sep 20. [Epub ahead of print] doi:10.1038/bmt.2010.203.
19. Qiao W, Zhao J, Wang C, Wang T, Xing Y. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Hematology 2010;15:21-27.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
21. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-3516. (Pubitemid 350159614)
22. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin's lymphoma. Cancer 2007;109:2481-2489. (Pubitemid 46906468)
23. Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E. The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006;91: 490-495.
24. Poulou LS, Thanos L, Ziakas PD. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging 2010;37:156-162.
25. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pre-transplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934-4937.
26. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522-1529.
27. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lympho-ma: results of the prospective multicenter H96 trial by the GELA/SFGM Study Group. J Clin Oncol 2008;26: 5980-5987.